Literature DB >> 27502752

Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy.

Gabriel Levy Hara1, Souha S Kanj2, Leonardo Pagani3, Lilian Abbo4, Andrea Endimiani5, Heiman F L Wertheim6, Carlos Amábile-Cuevas7, Pierre Tattevin8, Shaheen Mehtar9, Fernando Lopes Cardoso10, Serhat Unal11, Ian Gould12.   

Abstract

The Antibiotic Stewardship and Resistance Working Groups of the International Society for Chemotherapy propose ten key points for the appropriate use of antibiotics in hospital settings. (i) Get appropriate microbiological samples before antibiotic administration and carefully interpret the results: in the absence of clinical signs of infection, colonisation rarely requires antimicrobial treatment. (ii) Avoid the use of antibiotics to 'treat' fever: use them to treat infections, and investigate the root cause of fever prior to starting treatment. (iii) Start empirical antibiotic treatment after taking cultures, tailoring it to the site of infection, risk factors for multidrug-resistant bacteria, and the local microbiology and susceptibility patterns. (iv) Prescribe drugs at their optimal dosing and for an appropriate duration, adapted to each clinical situation and patient characteristics. (v) Use antibiotic combinations only where the current evidence suggests some benefit. (vi) When possible, avoid antibiotics with a higher likelihood of promoting drug resistance or hospital-acquired infections, or use them only as a last resort. (vii) Drain the infected foci quickly and remove all potentially or proven infected devices: control the infection source. (viii) Always try to de-escalate/streamline antibiotic treatment according to the clinical situation and the microbiological results. (ix) Stop unnecessarily prescribed antibiotics once the absence of infection is likely. And (x) Do not work alone: set up local teams with an infectious diseases specialist, clinical microbiologist, hospital pharmacist, infection control practitioner or hospital epidemiologist, and comply with hospital antibiotic policies and guidelines.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Antimicrobial resistance; Antimicrobial stewardship; Combination therapy; Prudent use of antibiotics

Mesh:

Substances:

Year:  2016        PMID: 27502752     DOI: 10.1016/j.ijantimicag.2016.06.015

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  18 in total

Review 1.  [Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].

Authors:  C Lanckohr; H Bracht
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

Review 2.  Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?

Authors:  Cédric Abat; Pierre-Edouard Fournier; Marie-Thérèse Jimeno; Jean-Marc Rolain; Didier Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-28       Impact factor: 3.267

3.  Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Franz Weber; Lucas Dübel; Agata Mikolajewska; Alexander Uhrig; Peggy Kiessling; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2022-06-02

4.  A Comparison of Nosocomial Infection Density in Intensive Care Units on Relocating to a New Hospital.

Authors:  Zeynep Ture; Tugba Ustuner; Ario Santini; Serhat Aydogan; İlhami Celik
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-08-11

5.  Amoxicillin Utilization Pattern at Governmental Hospitals in Eastern Ethiopia.

Authors:  Tigist Gashaw; Mekonnen Sisay; Tewodros Tesfa; Yohannes Baye; Firehiwot Amare
Journal:  Infect Drug Resist       Date:  2021-01-20       Impact factor: 4.003

6.  Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Authors:  Palma Manduzio
Journal:  Ther Clin Risk Manag       Date:  2017-02-13       Impact factor: 2.423

7.  Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.

Authors:  Yixue Wang; Zhiping Li; Weiming Chen; Gangfeng Yan; Guangfei Wang; Guoping Lu; Chao Chen
Journal:  J Clin Pharm Ther       Date:  2021-01-21       Impact factor: 2.512

8.  Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.

Authors:  Lisa Ehmann; Michael Zoller; Iris K Minichmayr; Christina Scharf; Barbara Maier; Maximilian V Schmitt; Niklas Hartung; Wilhelm Huisinga; Michael Vogeser; Lorenz Frey; Johannes Zander; Charlotte Kloft
Journal:  Crit Care       Date:  2017-10-21       Impact factor: 9.097

9.  [Antimicrobial stewardship programme implementation in a medical ward].

Authors:  J Ruiz; M Salavert; P Ramírez; M Montero; I Castro; E González; E Romá; J L Poveda
Journal:  Rev Esp Quimioter       Date:  2018-09-13       Impact factor: 1.553

10.  Anaerobic coverage as definitive therapy does not affect clinical outcomes in community-onset bacteremic biliary tract infection without anaerobic bacteremia.

Authors:  Pei-Shan Wu; Chien Chuang; Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang
Journal:  BMC Infect Dis       Date:  2018-06-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.